MX2020001615A - Compuestos de piridina sustituidos con azol. - Google Patents

Compuestos de piridina sustituidos con azol.

Info

Publication number
MX2020001615A
MX2020001615A MX2020001615A MX2020001615A MX2020001615A MX 2020001615 A MX2020001615 A MX 2020001615A MX 2020001615 A MX2020001615 A MX 2020001615A MX 2020001615 A MX2020001615 A MX 2020001615A MX 2020001615 A MX2020001615 A MX 2020001615A
Authority
MX
Mexico
Prior art keywords
sup
formula
azole
pyridine compound
compound substituted
Prior art date
Application number
MX2020001615A
Other languages
English (en)
Inventor
Madoka Kawamura
Hiroaki Tanaka
Yuji Ito
Ayako Bohno
Makoto Hamada
Yohei Kobashi
Kazuaki Suzuki
Kosuke Funayama
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2020001615A publication Critical patent/MX2020001615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto representado por la Fórmula [I] mostrada a continuación o una sal farmacéuticamente aceptable del mismo que tiene un efecto inhibidor sobre las enzimas que producen 20-HETE; (ver Fórmula) (en la Fórmula [I] anterior, la estructura representada por la Fórmula [II] abajo: (ver Fórmula) representa cualquiera de las estructuras representadas por el grupo de la Fórmula [III] a continuación: (ver Fórmulas) R1, R2, R3, y R4 representan independientemente un átomo de hidrógeno, un átomo de flúor, metilo, o similares; R5 representa cualquiera de las estructuras representadas por el grupo de fórmula [IV]: (ver Fórmulas).
MX2020001615A 2017-08-10 2018-08-10 Compuestos de piridina sustituidos con azol. MX2020001615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017171584 2017-08-10
PCT/JP2018/030456 WO2019031618A1 (ja) 2017-08-10 2018-08-10 アゾールで置換されたピリジン化合物

Publications (1)

Publication Number Publication Date
MX2020001615A true MX2020001615A (es) 2020-07-13

Family

ID=65271252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001615A MX2020001615A (es) 2017-08-10 2018-08-10 Compuestos de piridina sustituidos con azol.

Country Status (15)

Country Link
US (1) US11365192B2 (es)
EP (1) EP3666766A4 (es)
JP (1) JP7052798B2 (es)
KR (1) KR20200038457A (es)
CN (1) CN110914254A (es)
AU (1) AU2018312680A1 (es)
BR (1) BR112020002519A2 (es)
CA (1) CA3072420A1 (es)
IL (1) IL272482A (es)
MX (1) MX2020001615A (es)
PH (1) PH12020500292A1 (es)
RU (1) RU2020109674A (es)
SG (1) SG11202000976TA (es)
TW (1) TW201920134A (es)
WO (1) WO2019031618A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202045494A (zh) * 2019-02-08 2020-12-16 日商大正製藥股份有限公司 經雜芳基取代的吡啶化合物
CN115073308A (zh) * 2021-03-15 2022-09-20 苏州信礼发医药技术有限公司 1-氨甲基-1-环丙醇的合成方法
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN115557898A (zh) * 2021-07-01 2023-01-03 诸葛国琴 一种咪唑类化合物、其中间体及应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785148B1 (ko) 1999-11-01 2007-12-11 다이쇼 세이야꾸 가부시끼가이샤 20-ｈｅｔｅ 생산 효소 저해제
EP1294685A1 (en) 2000-06-29 2003-03-26 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JPWO2003022821A1 (ja) 2001-09-06 2004-12-24 大正製薬株式会社 ２０−ｈｅｔｅ産生酵素阻害作用を有するヘテロ環誘導体
JP2004262890A (ja) * 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
US20060189673A1 (en) 2003-04-14 2006-08-24 Nippon Soda Co., Ltd. Phenylazole compound, production process therefor and antioxidant
EP1650206A4 (en) 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
CN105492432B (zh) * 2013-07-31 2019-06-14 住友化学株式会社 四唑啉酮化合物及其用途
JP6351043B2 (ja) 2015-08-04 2018-07-04 株式会社ユニバーサルエンターテインメント 遊技機
US20210040062A1 (en) * 2016-02-15 2021-02-11 Taisho Pharmaceutical Co., Ltd. Azole-substituted pyridine compound

Also Published As

Publication number Publication date
EP3666766A4 (en) 2021-03-24
CN110914254A (zh) 2020-03-24
BR112020002519A2 (pt) 2020-08-04
PH12020500292A1 (en) 2021-01-25
RU2020109674A (ru) 2021-09-13
CA3072420A1 (en) 2019-02-14
US20210122741A1 (en) 2021-04-29
IL272482A (en) 2020-03-31
EP3666766A1 (en) 2020-06-17
WO2019031618A1 (ja) 2019-02-14
AU2018312680A1 (en) 2020-03-19
SG11202000976TA (en) 2020-03-30
WO2019031618A8 (ja) 2019-04-11
JP7052798B2 (ja) 2022-04-12
KR20200038457A (ko) 2020-04-13
JPWO2019031618A1 (ja) 2020-07-30
TW201920134A (zh) 2019-06-01
US11365192B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
MX2020001615A (es) Compuestos de piridina sustituidos con azol.
AU2018312326A2 (en) Heterocyclic compound and use thereof
MY192059A (en) Heterocyclic amides as kinase inhibitors
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MY196809A (en) (),()-unsaturated amide compound
MX2020006587A (es) Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
TN2017000483A1 (en) Triazole agonists of the apj receptor.
NZ718373A (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX2022002976A (es) Inhibidores selectivos de jak1.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MY192487A (en) Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
MX2020006613A (es) Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
CR20220251A (es) Nuevos derivados de metilquinazolinona
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
WO2018104729A8 (en) Ketamine derivatives
WO2018039077A8 (en) Therapeutic compounds
SG11201810725WA (en) Novel β-lactamase inhibitors
CR20200643A (es) Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2021013981A (es) Inhibidores de la cinasa aurora y usos de los mismos.